The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Interleukin-2 (IL-2) Mutein Therapies Market?

The interleukin-2 (il-2) mutein therapies market has seen rapid growth in its size in recent years. Its value is expected to increase from $0.73 billion in 2025 to $0.84 billion in 2026, representing a compound annual growth rate (CAGR) of 14.1%. This historical growth can be linked to advancements in cytokine engineering techniques, an enhanced understanding of immune signaling pathways, early positive clinical results from modified IL-2 therapies, a rise in investment within immuno-oncology research, and the increasing occurrence of immune-mediated diseases.

The interleukin-2 (il-2) mutein therapies market size is projected to experience substantial expansion in the coming years, with expectations to reach **$1.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%.** This anticipated growth over the forecast period stems from factors such as the broader adoption of personalized immunotherapy approaches, an increase in clinical trial activity for next-generation cytokines, a rising requirement for safer immune modulators, growing regulatory backing for innovative biologics, and an increase in partnerships formed between biotechnology and pharmaceutical companies. Significant trends during this period encompass the escalating development of receptor-biased il-2 muteins, a heightened focus on minimizing cytokine toxicity profiles, the expanded utilization of combination immunotherapy regimens, the proliferation of precision immune modulation strategies, and intensified clinical pipeline activity for both autoimmune and oncology indications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33185&type=smp

Which Significant Factors Are Encouraging Growth In The Interleukin-2 (IL-2) Mutein Therapies Market?

The heightened need for targeted immunotherapies is anticipated to fuel expansion within the interleukin-2 (IL-2) mutein therapies market. These specialized treatments are formulated to modify the immune system, enabling it to specifically target and eliminate cancer cells while minimizing harm to healthy tissues. The impetus for these therapies is growing as medical professionals and researchers increasingly seek safer and more potent alternatives to traditional chemotherapy and radiation therapy, which frequently entail considerable toxicity and lack specificity. IL-2 mutein therapies contribute to the progress of targeted immunotherapies by employing modified versions of interleukin-2 that selectively activate immune effector cells crucial for anti-tumor responses, simultaneously mitigating the activation of pathways linked to systemic toxicity. For example, in April 2025, the Cancer Research Institute, a US-based non-profit organization, reported that the FDA approved 17 new targeted immunotherapy agents in 2024, thereby broadening available choices for immune-based cancer treatment and enlarging the demographic of patients who could benefit from such interventions. Consequently, the rising demand for targeted immunotherapies is propelling the growth of the interleukin-2 (IL-2) mutein therapies market.

How Does Segment Analysis Break Down The Interleukin-2 (IL-2) Mutein Therapies Market Structure?

The interleukin-2 (il-2) mutein therapies market covered in this report is segmented –

1) By Product Type: Monotherapy; Combination Therapy

2) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations

3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Other Applications

4) By End User: Hospitals; Specialty Clinics; Research Institutes; Other End Users

Subsegments:

1) By Monotherapy: Single Agent Interleukin Two Mutein Therapy; Standalone Cytokine Based Immunotherapy; Targeted Immune Modulation Therapy

2) By Combination Therapy: Interleukin Two Mutein With Immune Checkpoint Inhibitors; Interleukin Two Mutein With Chemotherapy; Interleukin Two Mutein With Targeted Biologic Therapies; Interleukin Two Mutein With Cell Based Therapies

What Trends Are Influencing The Interleukin-2 (IL-2) Mutein Therapies Market Outlook?

Key players within the interleukin-2 (IL-2) mutein therapies market are increasingly prioritizing technological progress in cytokine-based immunotherapy, specifically focusing on the targeted activation of regulatory T-cells (Tregs) via engineered IL-2 muteins. This targeted Treg activation using engineered IL-2 muteins employs genetically altered IL-2 proteins crafted to selectively activate Tregs while concurrently restricting the stimulation of effector immune cells. As an illustration, Almirall S.A., a Spanish pharmaceutical firm, commenced the initial Phase I clinical investigation of its engineered IL-2 mutein fusion protein, ALM223, in December 2023. This study aims to assess its safety, pharmacokinetics, immunogenicity, and pharmacodynamics in the context of autoimmune diseases. This specific candidate incorporates features like selective Treg activation, a modified Fc fusion designed to enhance molecular stability, and an optimized cytokine backbone engineered for superior immune modulation. Although these technological strides underscore the potential of IL-2 muteins for precise immunomodulation and wider application in autoimmune conditions, their actual clinical effectiveness and sustained safety profiles still require confirmation through current and upcoming trials.

Who Are The Key Market Participants In The Interleukin-2 (IL-2) Mutein Therapies Market?

Major companies operating in the interleukin-2 (il-2) mutein therapies market are Merck & Co. Inc., Sanofi S.A., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Lonza Group AG, Alkermes plc, BioNTech SE, Xencor Inc., Innovent Biologics Inc., Ascendis Pharma A/S, ShanghAI Junshi Biosciences Co. Ltd., Mural Oncology Inc., ProBioGen AG, Werewolf Therapeutics Ltd., Philogen S.p.A., Cue Biopharma Inc., Medicenna Therapeutics Corp., Bright Peak Therapeutics Inc., Iovance Biotherapeutics Inc.

Access The Complete Interleukin-2 (IL-2) Mutein Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/interleukin-2-il-2-mutein-therapies-market-report

Which Region Is The Dominant Market In The Interleukin-2 (IL-2) Mutein Therapies Market?

North America was the largest region in the interleukin 2 (IL-2) mutein therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin-2 (il-2) mutein therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Interleukin-2 (IL-2) Mutein Therapies Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model